{
  "scan_date": "2026-02-05",
  "scan_time": "2026-02-05T16:26:27.755255",
  "summary": {
    "fda_new": 11,
    "ema_new": 0,
    "mfds_new": 0,
    "total_new": 11,
    "hot_issues": 5
  },
  "fda_new": [
    {
      "source": "fda",
      "drug_name": "LORBRENA",
      "generic_name": "LORLATINIB",
      "approval_date": "2018-11-02",
      "application_number": "NDA210868",
      "indication": "Kinase Inhibitor [EPC]",
      "sponsor": "PFIZER",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "SERTRALINE HYDROCHLORIDE",
      "generic_name": "SERTRALINE HYDROCHLORIDE",
      "approval_date": "2026-01-29",
      "application_number": "ANDA220275",
      "indication": "",
      "sponsor": "ZYDUS LIFESCIENCES",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "LACOSAMIDE ORAL SOLUTION",
      "generic_name": "LACOSAMIDE ORAL",
      "approval_date": "2026-01-29",
      "application_number": "ANDA220386",
      "indication": "",
      "sponsor": "INDOCO",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": false,
      "existing_approvals": []
    },
    {
      "source": "fda",
      "drug_name": "LYBALVI",
      "generic_name": "OLANZAPINE AND SAMIDORPHAN L-MALATE",
      "approval_date": "2021-05-28",
      "application_number": "NDA213378",
      "indication": "Atypical Antipsychotic [EPC]",
      "sponsor": "ALKERMES INC",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": false,
      "existing_approvals": []
    },
    {
      "source": "fda",
      "drug_name": "GABAPENTIN",
      "generic_name": "GABAPENTIN",
      "approval_date": "2003-09-12",
      "application_number": "ANDA075350",
      "indication": "",
      "sponsor": "ACTAVIS ELIZABETH",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "ENBREL",
      "generic_name": "ETANERCEPT",
      "approval_date": "1998-11-02",
      "application_number": "BLA103795",
      "indication": "Tumor Necrosis Factor Blocker [EPC]",
      "sponsor": "IMMUNEX",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 35,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인",
        "고관심 적응증 (tumor)"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "WEGOVY",
      "generic_name": "SEMAGLUTIDE",
      "approval_date": "2025-12-22",
      "application_number": "NDA218316",
      "indication": "GLP-1 Receptor Agonist [EPC]",
      "sponsor": "NOVO",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "CETIRIZINE HCL",
      "generic_name": "CETIRIZINE HCL",
      "approval_date": "2009-07-23",
      "application_number": "NDA022429",
      "indication": "",
      "sponsor": "BIONPHARMA",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": true,
      "existing_approvals": [
        "fda"
      ]
    },
    {
      "source": "fda",
      "drug_name": "GABAPENTIN",
      "generic_name": "GABAPENTIN",
      "approval_date": "2017-03-24",
      "application_number": "ANDA207099",
      "indication": "",
      "sponsor": "RISING",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "none",
      "hot_issue_score": 0,
      "hot_issue_reasons": [],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "WEGOVY",
      "generic_name": "SEMAGLUTIDE",
      "approval_date": "2021-06-04",
      "application_number": "NDA215256",
      "indication": "GLP-1 Receptor Agonist [EPC]",
      "sponsor": "NOVO",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "LIVDELZI",
      "generic_name": "SELADELPAR LYSINE",
      "approval_date": "2024-08-14",
      "application_number": "NDA217899",
      "indication": "",
      "sponsor": "GILEAD SCIENCES INC",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "ema"
      ]
    }
  ],
  "ema_new": [],
  "mfds_new": [],
  "hot_issues": [
    {
      "source": "fda",
      "drug_name": "ENBREL",
      "generic_name": "ETANERCEPT",
      "approval_date": "1998-11-02",
      "application_number": "BLA103795",
      "indication": "Tumor Necrosis Factor Blocker [EPC]",
      "sponsor": "IMMUNEX",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 35,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인",
        "고관심 적응증 (tumor)"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "LORBRENA",
      "generic_name": "LORLATINIB",
      "approval_date": "2018-11-02",
      "application_number": "NDA210868",
      "indication": "Kinase Inhibitor [EPC]",
      "sponsor": "PFIZER",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "WEGOVY",
      "generic_name": "SEMAGLUTIDE",
      "approval_date": "2025-12-22",
      "application_number": "NDA218316",
      "indication": "GLP-1 Receptor Agonist [EPC]",
      "sponsor": "NOVO",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "WEGOVY",
      "generic_name": "SEMAGLUTIDE",
      "approval_date": "2021-06-04",
      "application_number": "NDA215256",
      "indication": "GLP-1 Receptor Agonist [EPC]",
      "sponsor": "NOVO",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "fda",
        "ema",
        "mfds"
      ]
    },
    {
      "source": "fda",
      "drug_name": "LIVDELZI",
      "generic_name": "SELADELPAR LYSINE",
      "approval_date": "2024-08-14",
      "application_number": "NDA217899",
      "indication": "",
      "sponsor": "GILEAD SCIENCES INC",
      "is_breakthrough": false,
      "is_accelerated": false,
      "is_orphan": false,
      "is_prime": false,
      "hot_issue_type": "global_concurrent",
      "hot_issue_score": 25,
      "hot_issue_reasons": [
        "FDA+EMA 동시 승인"
      ],
      "matched_existing": true,
      "existing_approvals": [
        "fda",
        "ema"
      ]
    }
  ],
  "errors": []
}